for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Innovent Biologics Inc

1801.HK

Latest Trade

65.60HKD

Change

0.90(+1.39%)

Volume

4,013,660

Today's Range

65.20

 - 

67.55

52 Week Range

54.50

 - 

107.10

As of on the Hong Kong Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
64.70
Open
65.55
Volume
4,013,660
3M AVG Volume
119.94
Today's High
67.55
Today's Low
65.20
52 Week High
107.10
52 Week Low
54.50
Shares Out (MIL)
1,460.09
Market Cap (MIL)
94,468.12
Forward P/E
-48.34
Dividend (Yield %)
--

Next Event

Innovent Biologics Inc Annual Shareholders Meeting

Latest Developments

More

Innovent Biologics Says PD-1 Inhibitor Tyvyt Successfully Included In Updated NDRL

Innovent Biologics Says NMPA Approved Novel Drug Olverembatinib To Treat Chronic Myeloid Leukemia

Innovent Biologics Says NMPA Accepted Supplemental NDA For TYVYT

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Innovent Biologics Inc

Innovent Biologics Inc is an investment holding company principally engaged in biopharmaceuticals. The Company and its subsidiaries are engaged in research and development of antibody and protein medicine products, sale and distribution of pharmaceutical products, and provision of consultation and research and development services. The Company's main product is Tyvyt (sintilimab injection), which is used to treat relapsed or refractory classical Hodgkin’s lymphoma. The Company's products also include adalimumab biosimilar IBI-303, which is used to treat rheumatoid arthritis, ankylosing spondylitis and psoriasis. Bevacizumab biosimilar IBI-305 is used to treat metastatic colorectal cancer and advanced, metastatic or recurrent non-small-cell lung cancer (NSCLC). Rituximab biosimilar IBI-301 is used to treat non-Hodgkin's lymphoma and chronic lymphocytic leukemia. Its products are used in oncology, metabolic, immunology and ophthalmology diseases.

Industry

Biotechnology & Drugs

Contact Info

168

Dongping Street, Suzhou Industrial Park

SUZHOU, JNG

215123

China

http://innoventbio.com/#/

Executive Leadership

De-Chao Yu

Executive Chairman of the Board, Chief Executive Officer

Yong Jun Liu

President

Hao Xi Ede

Chief Financial Officer, Executive Director

Lok Yee Chan

Joint Company Secretary

Yanju Wang

Joint Company Secretary

Key Stats

1.57 mean rating - 21 analysts
Sell
Hold
Buy
Revenue (MM, CNY)

2018

0.0K

2019

1.0K

2020

3.8K

2021(E)

4.2K
EPS (CNY)

2018

-17.240

2019

-1.460

2020

-0.740

2021(E)

-1.063
Price To Earnings (TTM)
--
Price To Sales (TTM)
16.08
Price To Book (MRQ)
6.48
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
15.59
LT Debt To Equity (MRQ)
12.36
Return on Investment (TTM)
-14.18
Return on Equity (TTM)
-12.32

Latest News

Latest News

Analysis-China's biotech sector comes of age with big licensing deals, global ambitions

If investors in China's biotech industry needed one more sign that the sector is coming of age, then a major licensing deal RemeGen Co Ltd struck last month with Seattle-based Seagen Inc fits the bill.

BRIEF-Innovent Biologics Says NMPA Granted Marketing Approval For Byvasda (Bevacizumab Biosimilar) In China

* INNOVENT BIOLOGICS INC- NMPA GRANTED MARKETING APPROVAL FOR BYVASDA (BEVACIZUMAB BIOSIMILAR) IN CHINA Source text for Eikon: Further company coverage:

BRIEF-Innovent Biologics Says Unit Entered Strategic Collaboration Agreement With Roche Group

* UNIT ENTERED STRATEGIC COLLABORATION AGREEMENT WITH ROCHE GROUP

BRIEF-Innovent Biologics Enters Strategic Collaboration Agreement With University Of Texas MD Anderson Cancer Center

* INNOVENT BIOLOGICS INC- ENTERED INTO A STRATEGIC COLLABORATION AGREEMENT WITH UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER

BRIEF-Innovent Biologics Says Study Of TYVYT Met Primary Endpoint Of Overall Survival

* PHASE 2 ORIENT-2 STUDY INVESTIGATING TYVYT MET PRIMARY ENDPOINT OF OVERALL SURVIVAL Source text for Eikon: Further company coverage:

BRIEF-Innovent Biologics Updates On Phase 3 ORIENT-12 Study On Squamous NSCLC

* UPDATES ON PHASE 3 ORIENT-12 STUDY INVESTIGATING TYVYT IN COMBINATION WITH GEMZAR & PLATINUM CHEMOTHERAPY FOR SQUAMOUS NSCLC

BRIEF-Innovent And Eli Lilly Announce NMPA Acceptance Of Supplemental New Drug Application For Sintilimab

* INNOVENT AND ELI LILLY ANNOUNCE NMPA ACCEPTANCE OF A SUPPLEMENTAL NEW DRUG APPLICATION FOR SINTILIMAB IN COMBINATION WITH ALIMTA® (PEMETREXED) Source text for Eikon: Further company coverage:

BRIEF-Innovent Biologics Says China's NMPA Accepted Supplemental New Drug Application For Tyvyt

* CHINA'S NMPA ACCEPTED SUPPLEMENTAL NEW DRUG APPLICATION FOR TYVYT Source text for Eikon: Further company coverage:

BRIEF-Innovent Biologics Says Revenue Attributable To Sales Of Tyvyt (Sintilimab Injection) In Q1 Around Rmb400 Million

* REVENUE ATTRIBUTABLE TO SALES OF TYVYT (SINTILIMAB INJECTION) IN Q1 AROUND RMB400 MILLION Source text for Eikon: Further company coverage:

BRIEF-Innovent Biologics Says U.S. FDA Approves Pemazyre (Pemigatinib) For Metastatic Cholangiocarcinoma

* U.S. FDA APPROVES PEMAZYRE (PEMIGATINIB) FOR ADULTS WITH UNRESECTABLE LOCALLY ADVANCED OR METASTATIC CHOLANGIOCARCINOMA Source text for Eikon: Further company coverage:

BRIEF-Innovent Biologics' FY Total Revenue RMB1,047.5 Mln

* FY TOTAL REVENUE WAS RMB1,047.5 MILLION VERSUS RMB9.5 MILLION

Drugmakers slash prices in China to get on reimbursement list

Drugmakers including Roche <ROG.S> and Novartis' <NOVN.S> have agreed to cut the prices of some of their newest drugs by an average of 61% in China in order to get on a national reimbursement scheme list, regulators said.

UPDATE 2-Shanghai Junshi Biosciences soars on HK debut after $394 mln IPO

* Junshi Biosciences taking advantage of new listing rules in HK

UPDATE 1-China's Junshi Biosciences raises $394 mln after pricing IPO at bottom of range -sources

Chinese biotech startup Shanghai Junshi Biosciences Co Ltd has raised $394 million after pricing its Hong Kong initial public offering (IPO) at the bottom of a marketed range, two people familiar with the share sale said on Monday.

China's Junshi Biosciences raises $394 mln after pricing IPO at bottom of range -sources

Chinese biotech startup Shanghai Junshi Biosciences Co Ltd has raised $394 million after pricing its Hong Kong initial public offering (IPO) at the bottom of a marketed range, two people familiar with the share sale said on Monday.

China biotech Junshi Biosciences seeks up to $414 million in Hong Kong IPO

Chinese biotech company Shanghai Junshi Biosciences is seeking up to $414 million in a Hong Kong initial public offering (IPO), making it the latest company to take advantage of new listing rules to attract early-stage drug developers.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up